Focus on raloxifene: A selective estrogen receptor modulator for prevention of osteoporosis in postmenopausal women

Raloxifene HCl is a selective estrogen receptor modulator of the benzothiophene class that binds to the estrogen receptor with high affinity. It was approved by the FDA late last year for prevention of osteoporosis in postmenopausal women In clinical trials, raloxifene has exhibited a protective effect against postmenopausal bone loss for up to 2 years with minimal estrogenic effects on the endometrium. It appears to have a positive effect on the lipid profile and may be protective against breast cancer Its influence on cardiovascular mortality is uncertain, however, and its effects on bone fracture risk have yet to be determined Hot flashes and leg cramps were the most common drug-related side effects in premarketing trials; the drug also was associated with increased risk of venous thromboembolism. Addition of raloxifene to the formulary seems appropriate if patient selection criteria and ongoing drug use evaluations are in place.